Another article on Satri Cel, a CART therapy targeting claudin 18.2 on gastric cancer.
just completed enrolment of phase 2 pivotal trial.
CHM CDH17 groundbreaking study has strong parallels to Satie Cel but important differences:
a) CDH17 targets a different protein (CDH17) which is more common than claudin 18.2
b) CDH17 trial is a phase 1/2 such that the company can immediately move to phase 2 (potentially registrational) after proving safe and showing some efficacy in phase 1
https://www.prnewswire.com/news-releases/carsgen-announces-enrollment-completion-in-china-gcgej-pivotal-phase-ii-clinical-trial-of-the-first-in-class-claudin18-2-car-t-satri-cel-302225000.html
Another article on Satri Cel, a CART therapy targeting claudin...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $69.79K | 17.44M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 26298938 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 9548289 | 12 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |